We read with great interest the paper of Fonseca et al. 1 published on your journal and would like to make some considerations about this study.
The authors studied a small sample of predominantly Hispanic neonates, and although the high risk of hyperbilirubinemia in this population, they started phototherapy at very low total serum bilirubin (TSB) levels for term infants. The authors state that phototherapy was started according to the American Academy of Paediatrics guidelines. However, the reported TSB levels before phototherapy are very low to justify the treatment in the absence of hemolysis. Did the authors use prophylactic phototherapy? Tan and Dong 2 started phototherapy at really higher levels than those reported by Fonseca et al.
Surprisingly, TSB and transcutaneous bilirubin in covered skin (TcB-C) did not change during treatment, whereas transcutaneous bilirubin in exposed skin significantly decreased. How is this possible? It would have been relevant to know the ranges of TSB for each time point of evaluation, as well as the peak TSB reached by each infant. We recently published a paper on 364 newborn infants obtaining different results. 3 In fact, in our study we found similar significant reductions of TSB (from 13.6 ± 3.8 to 9.2±3.3 mg dl À1 ) and TcB-C (from 13.3±3.5 to 9.0 ± 3.6 mg dl À1 ) after 52 ± 33 h of phototherapy. The authors state they measured bilirubin levels on a 12-hourly basis while receiving phototherapy, but in Table 2 the mean age of life after 36 and 48 h of treatment is 82.4 and 105 h respectively: why? Moreover, the initially small sample size further decreases after the first 24 h of treatment, leaving only 14 measurements at 48 h.
The authors evaluated the rebound 6 h after phototherapy discontinuation but the mean TSB and TcB-C were even lower than the last measurement during treatment. It is hard to accept the concept of rebound with still decreasing bilirubin levels and after just 6 h of discontinuation, considering that TSB rebound is generally observed 24 h after phototherapy interruption. Data on duration of phototherapy in each patient (mean±s.d.) could have been probably useful in understanding what really happened.
As for further studies on infants of different gestational age, the authors omitted to quote our paper in which we stated that the difference between covered and uncovered skin bilirubin levels is lower in preterm than in term infants. This can be explained by the immaturity of the epidermis and by the lack of substantial subcutaneous fat that have a role in the early balance between skin and serum bilirubins.
Finally, we would add another information in this field. Plotting the difference between TSB and TcB-C against the cumulative hours of phototherapy, we observed that TcB-C begins to underestimates TSB only after 96 h of treatment. This observation allows the use of TcB-C to control babies under phototherapy, significantly reducing the need for blood draws.
